Prolongation of Cardiac and Islet Allograft Survival by a Blocking Hamster Anti-Mouse CXCR3 Monoclonal Antibody
- 15 July 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 86 (1) , 137-147
Abstract
Background. Acute allograft rejection requires a multifaceted immune response involving trafficking of immune cells into the transplant and expression of effector cell functions leading to graft destruction. The chemokine receptor CXCR3 and its ligands, CXCL9, CXCL10 and CXCL11, constitute an important pathway for effector cell recruitment posttransplant. However, analysis of CXCR3 expression and function has been hampered by a general lack of availability of a neutralizing anti-CXCR3 monoclonal antibody (mAb) for use in experimental models. Methods. We report the generation, characterization, and use of CXCR3-173, a new hamster mAb specific for mouse CXCR3 that recognizes CXCR3 on cells from wild-type but not CXCR3−/− mice. Results. Using CXCR3-173 mAb, we demonstrate CXCR3 expression on primary memory phenotype CD4+ and CD8+ T cells, naturally occurring CD4+CD25+ Foxp3+ regulatory T cells, natural killer T cells, and approximately 25% of NK cells. CXCR3-173 blocked chemotaxis in vitro in response to CXCL10 or CXCL11 but not CXCL9. When injected into mice, this mAb significantly prolonged both cardiac and islet allograft survival. When combined with a subtherapeutic regimen of rapamycin, CXCR3-173 mAb induced long-term (>100 day) survival of cardiac and islet allografts. The in vivo effects of CXCR3-173 mAb were not associated with effector lymphocyte depletion. Conclusion. These data highlight the utility of CXCR3-173 mAb in developing immunotherapeutic approaches to inhibit transplant rejection and potentially other immune-mediated diseases in murine models.Keywords
This publication has 34 references indexed in Scilit:
- Programmed cell death 1 (PD‐1) and its ligand PD‐L1 are required for allograft toleranceEuropean Journal of Immunology, 2007
- Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7Proceedings of the National Academy of Sciences, 2007
- Organ-Specific Differences in the Function of MCP-1 and CXCR3 During Cardiac and Skin Allograft RejectionTransplantation, 2007
- A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor developmentJournal of Experimental Medicine, 2006
- CXCR3 Requires Tyrosine Sulfation for Ligand Binding and a Second Extracellular Loop Arginine Residue for Ligand-Induced ChemotaxisMolecular and Cellular Biology, 2006
- Regulatory T Cell Lineage Specification by the Forkhead Transcription Factor Foxp3Immunity, 2005
- Induced recruitment of NK cells to lymph nodes provides IFN-γ for TH1 primingNature Immunology, 2004
- CXC chemokines in angiogenesis of cancerSeminars in Cancer Biology, 2004
- Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi‐step model of ligand binding and receptor activationEuropean Journal of Immunology, 2003
- Survival Of Mhc-Deficient Mouse Heterotopic Cardiac AllograftsTransplantation, 1995